stride trial semaglutide Post hoc analysis of found had a beneficial effect on functional outcomes in people with peripheral artery disease and type 2 diabetes regardless of type 2 diabetes characteristics. @ADA_Pubs Read Design and baseline characteristics of

A Sunlight survey found that GLP-1 users spend $218 less on groceries, fast food, snacks, dining out, and diet programs.

Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic

The primary endpoint is the semaglutideplacebo difference on change from baseline to week 104 in the Clinical Dementia Rating Sum of Boxes score

We evaluated available evidence by searching PubMed and EMBASE databases, according to specific inclusion and exclusion eligibility criteria to evaluate gastrointestinal adverse events associated with GLP-1 RAs in non-diabetic individuals with overweight or obesity

Insurance coverage for GLP-1 medications remains selective, but proven appeal strategies and affordable compounded options can help you access treatment today without delays